40 completed, 17 recruiting, 14 terminated, 4 not yet recruiting. 79 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 79 | Completed 40, Recruiting 17, Terminated 14, Not yet recruiting 4, Active not recruiting 2, Withdrawn 2 |
Follow VA Office of Research and Development: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating an Innovative Tobacco Treatment Approach for Veterans in Substance Use Treatment Healthy Changes Nicotine Replacement Therapy (NRT), Cessation Treatment Nicotine Replacement Therapy (NRT), Cessation Treatment Counseling - Cigarette Smoking, Veterans | Phase 4 | Not yet recruiting | VA Office of Research and Development | 112 | 2027-04-01 | 2026-09-14 |
| Assessing Trauma-related Links Between Affective and Metabolic Systems prazosin - Posttraumatic Stress Disorder, Metabolic Syndrome | Phase 4 | Not yet recruiting | VA Office of Research and Development | 70 | 2027-03-01 | 2026-10-15 |
| Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease mirabegron, Exercise-based behavioral therapy - Overactive Bladder, Parkinson Disease | Phase 4 | Not yet recruiting | VA Office of Research and Development | 146 | 2026-11-09 | 2026-10-27 |
| Central Apnea in Heart Failure: Physiological Mechanisms to Inform Treatment Trazodone + positive airway pressure (PAP) therapy, Oxygen + positive airway pressure (PAP) therapy - Sleep Disordered Breathing, Able Bodied | Phase 4 | Recruiting | VA Office of Research and Development | 200 | 2026-09-16 | 2026-10-13 |
| Varenicline for Smoking Reduction in Veterans Not Ready To Quit Motivation-Phase Varenicline, Motivation-Phase Nicotine Mini-Lozenge, Cessation-Phase Combination Nicotine Replacement Therapy (NRT) - Veterans, Tobacco Use Disorder | Phase 4 | Recruiting | VA Office of Research and Development | 400 | 2026-08-17 | 2026-08-31 |
| Comparing the Safety and Efficacy of Apixaban and Rivaroxaban Apixaban, Rivaroxaban - Atrial Fibrillation | Phase 4 | Recruiting | VA Office of Research and Development | 10000 | 2026-06-01 | 2026-09-23 |
| The Effects of Orexin Antagonism on Fear Extinction in PTSD Suvorexant, Placebo - Insomnia, PTSD | Phase 4 | Not yet recruiting | VA Office of Research and Development | 40120 | 2026-06-01 | 2026-06-02 |
| Atomoxetine and Executive Function in PTSD Atomoxetine, Placebo - Posttraumatic Stress Disorder With Attention Defic | Phase 4 | Recruiting | VA Office of Research and Development | 160 | 2026-04-01 | 2026-07-07 |
| Randomized Trial of SGLT2i in Heart Transplant Recipients Empagliflozin, Placebo - Heart Transplant, Cardiovascular Disease | Phase 4 | Recruiting | VA Office of Research and Development | 200 | 2026-01-20 | 2026-01-22 |
| Better Options for Chronic Cancer Pain Multimodal pain care, Medication optimization, Buprenorphine rotation - Chronic Pain, Cancer Survivor | Phase 4 | Recruiting | VA Office of Research and Development | 294 | 2025-10-07 | 2026-05-11 |
| Computational Assessment of GABA Receptor Modulation in PTSD Lorazepam 1 mg tablet, Placebo tablet - Stress Disorders, Post-Traumatic | Phase 4 | Recruiting | VA Office of Research and Development | 150 | 2025-07-01 | 2026-06-16 |
| Empagliflozin Treatment in Kidney Transplant Recipients Empagliflozin - Kidney Transplant, Chronic Kidney Disease | Phase 4 | Recruiting | VA Office of Research and Development | 264 | 2024-04-05 | 2026-04-21 |
| Methylphenidate for the Treatment of PTSD With Associated Neurocognitive Complaints Methylphenidate, Placebo - Posttraumatic Stress Disorder (PTSD) | Phase 4 | Recruiting | VA Office of Research and Development | 70 | 2024-02-05 | 2026-08-19 |
| VA Aripiprazole vs Esketamine for Treatment Resistant Depression Esketamine, Aripiprazole - Depressive Disorder, Major | Phase 4 | Withdrawn | VA Office of Research and Development | 2023-10-27 | 2024-01-05 | |
| The Peri-OPerative COlchicine to Reduce Negative Events (POPCORN) Trial Colchicine, Placebo - Coronary Artery Disease | Phase 4 | Recruiting | VA Office of Research and Development | 700 | 2023-08-21 | 2026-04-22 |
| Methylphenidate for the Treatment of Epilepsy-related Cognitive Deficits Methylphenidate, Placebo - Epilepsy | Phase 4 | Recruiting | VA Office of Research and Development | 226 | 2023-08-14 | 2026-04-20 |
| Investigation of Metformin in Pre-Diabetes on Atherosclerotic Cardiovascular OuTcomes Metformin XR, Placebo - Prediabetic State, Atherosclerosis | Phase 4 | Recruiting | VA Office of Research and Development | 7410 | 2023-04-03 | 2025-12-17 |
| Diuretics and Volume Overload in Early CKD Diuretic augmentation (hydrochlorothiazide, chlorthalidone, furosemide, torsemide, or bumetanide) - Chronic Kidney Disease, Hypertension | Phase 4 | Completed | VA Office of Research and Development | 49 | 2023-02-01 | 2026-09-21 |
| Pimavanserin vs. Quetiapine for Treatment of Parkinson's Psychosis Pimavanserin, Quetiapine - Parkinson's Disease Psychosis | Phase 4 | Recruiting | VA Office of Research and Development | 358 | 2022-10-24 | 2026-08-19 |
| CBT-I Augmentation of Medication for Drinking in AUD Cognitive Behavioral Therapy for Insomnia, Sleep Hygiene Education - Alcohol Use Disorder With Insomnia | Phase 4 | Terminated | VA Office of Research and Development | 82 | 2022-06-15 | 2025-02-28 |
Showing 20 of 79. Sign in to see all of them.
Stress Disorders, Post-Traumatic (15) · Renal Insufficiency, Chronic (5) · Dementia (4) · Diabetes Mellitus (4) · Diabetes Mellitus, Type 2 (4) · Sleep Apnea Syndromes (4) · Alcoholism (3) · Alzheimer Disease (3) · Attention Deficit Disorder with Hyperactivity (3) · Cardiovascular Diseases (3) · Coronary Artery Disease (3) · Sleep Initiation and Maintenance Disorders (3) · Smoking (3) · Atherosclerosis (2) · Brain Injuries, Traumatic (2)
Bupropion (3) · Methylphenidate (3) · Nicotine (3) · Nicotine Chewing Gum (3) · Acetazolamide (2) · Atomoxetine Hydrochloride (2) · Chlorhexidine (2) · Cognitive Behavioral Therapy (2) · Oxygen (2) · Prazosin (2) · Propranolol (2) · Quetiapine Fumarate (2) · Sertraline (2) · Sugars (2) · Testosterone (2)
United States (79) · Puerto Rico (1)
Sabra S Inslicht, PhD (3) · Binita Shah, MD (2) · M Safwan Badr, MD (2) · Sarah M. Wilson, PhD (2) · Zhewu Wang, MD (2) · Ali A El-Solh, MD MPH (1) · Alvin M Matsumoto, MD (1) · Andrea Snow, PhD MS BS (1) · Anna J Jovanovich, MD (1) · Beth A Leeman-Markowski, MD (1) · Calin Ioan Prodan, MD (1) · Cara N Pellegrini (1) · Dale N Gerding, MD (1) · Daniel J Gottlieb, MD MPH (1) · Daniel M Musher (1)
PMID 19773791, PMID 19826022, PMID 20145222, PMID 20220576, PMID 21575967, PMID 21900095, PMID 22163081, PMID 22237512, PMID 22640466, PMID 22773022, PMID 23116986, PMID 23171095, PMID 24490269, PMID 25238728, PMID 25409287, PMID 25441015, PMID 26598115, PMID 26625355, PMID 27149635, PMID 27207349, PMID 27465252, PMID 27543222, PMID 27627802, PMID 28088997, PMID 28112433, PMID 28160528, PMID 28500658, PMID 28532759, PMID 28621489, PMID 28669290, PMID 28877312, PMID 28945120, PMID 29241779, PMID 29299592, PMID 29759512, PMID 30508548, PMID 30896781, PMID 31141634, PMID 31332029, PMID 31647464, PMID 31914940, PMID 32019343, PMID 32295417, PMID 32521100, PMID 32880186, PMID 32969781, PMID 33047438, PMID 33718653, PMID 34362264, PMID 34400461
1IK2CX002030-01 (1), 1IK2CX002368-01A1 (1), I01CX001449 (1), I01CX001665 (1), I01CX001814 (1), I01CX001944 (1), I01CX001957 (1), I01CX002358 (1), I01CX002902 (1), I01RD000466 (1), I01RD001576 (1), I01RX003143 (1), I01RX004823 (1), I21RX002180 (1)